Stockscreener 앱 받기
12.98
0.47%
0.14
전일 마감가:
$12.84
열려 있는:
$12.78
하루 거래량:
184.36K
Relative Volume:
0.90
시가총액:
$221.69M
수익:
$10.73M
순이익/손실:
$-455.74M
주가수익비율:
-3.4312
EPS:
-3.7829
순현금흐름:
$-502.70M
1주 성능:
+5.39%
1개월 성능:
+6.17%
6개월 성능:
-82.29%
1년 성능:
-72.24%
1일 변동 폭
$12.78
$13.35
1주일 범위
$12.03
$13.35
52주 변동 폭
$11.13
$73.06
어비디티 바이오사이언스 Stock (RNA) Company Profile
명칭
Atrium Therapeutics Inc
전화
858-401-7900
주소
3020 CALLAN ROAD, SAN DIEGO, CA
Compare RNA vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNA
Atrium Therapeutics Inc
|
12.96 | 219.64M | 10.73M | -455.74M | -502.70M | -3.7829 |
VRTX
Vertex Pharmaceuticals Inc
|
515.47 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.53 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.02 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.00 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.46 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
어비디티 바이오사이언스 Stock (RNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-11 | 개시 | Wells Fargo | Overweight |
| 2025-09-17 | 개시 | Roth Capital | Buy |
| 2025-07-10 | 재개 | Goldman | Buy |
| 2025-06-24 | 개시 | Bernstein | Outperform |
| 2025-06-17 | 개시 | Wolfe Research | Outperform |
| 2025-06-11 | 개시 | Raymond James | Strong Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-20 | 개시 | H.C. Wainwright | Buy |
| 2024-11-26 | 개시 | RBC Capital Mkts | Outperform |
| 2024-09-24 | 개시 | Goldman | Buy |
| 2024-08-28 | 개시 | Barclays | Overweight |
| 2024-05-03 | 개시 | BofA Securities | Buy |
| 2024-03-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-05-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-03-31 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-07-20 | 개시 | Chardan Capital Markets | Buy |
| 2022-07-12 | 개시 | Raymond James | Strong Buy |
| 2021-09-07 | 개시 | Evercore ISI | Outperform |
| 2021-06-17 | 개시 | Needham | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-07-07 | 개시 | Cowen | Outperform |
| 2020-07-07 | 개시 | Credit Suisse | Outperform |
| 2020-07-07 | 개시 | SVB Leerink | Outperform |
| 2020-07-07 | 개시 | Wells Fargo | Overweight |
모두보기
어비디티 바이오사이언스 주식(RNA)의 최신 뉴스
Atrium Therapeutics, Inc. (RNA) Stock Analysis: 94.70% Potential Upside Catches Investor Attention - directorstalkinterviews.com
Atrium Therapeutics (RNA): RA Capital and affiliates report 0% beneficial ownership - Stock Titan
Sessa Capital discloses 8.8% Atrium Therapeutics (RNA) ownership through managed funds - Stock Titan
T. Rowe Price Associates (RNA) discloses 8.6% Atrium Therapeutics ownership in 13G/A - Stock Titan
Atrium Therapeutics, Inc.: Financial Data Forecasts Estimates and Expectations | RNA | US04965N1046 - marketscreener.com
Atrium Therapeutics Q2 Net Loss Widens to $21.6 Million on Higher Spending - Minichart
Atrium Therapeutics Earns $15M BMS Milestone Payment, Advances Gene Therapy Candidate - Minichart
Form 8K Atrium Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
Heart drug developer Atrium Therapeutics' Q2 loss widens as expenses rise - TradingView
Atrium Therapeutics Q2 Results: Sales beat 50%, EPS miss widens - scanx.trade
Atrium Therapeutics, Inc. Q2 2026: Revenue $3M, EPS $(1.18) — 10-Q Summary - TradingView
Atrium Therapeutics (RNA) grows collaboration revenue to $22.6M while scaling R&D spend - Stock Titan
Atrium Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
META_TITLE_QUOTE - Yahoo Finance
Atrium Therapeutics Reports Second Quarter 2026 Financial Results - kitv.com
Fierce Biotech Fundraising Tracker '26: InduPro assembles $77M; Vaderis nets $152M series B - Fierce Biotech
Atrium Therapeutics Earns $15M BMS Milestone - Contract Pharma
Atrium Therapeutics receives $15m milestone from Bristol Myers Squibb By Investing.com - Investing.com Nigeria
Atrium Therapeutics Earns Another $15 Million Milestone Payment From Bristol Myers Squibb - marketscreener.com
Atrium Therapeutics receives $15m milestone from Bristol Myers Squibb - Investing.com
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration - PR Newswire
Atrium Therapeutics, Inc. (RNA) Stock Analysis: Exploring a Potential 102.59% Upside in the Booming RNA Therapeutics Market - directorstalkinterviews.com
H.C. Wainwright Initiates Atrium Therapeutics(RNA.US) With Buy Rating, Announces Target Price $25 - Moomoo
This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Sahm
Atrium Therapeutics (RNA) Climbs 1.99% to $11.77, Approaching Key Resistance at $12.36Volume Oscillator - dars.gov.et
Atrium Therapeutics, Inc. (RNA) Stock Analysis: A 120% Upside Potential Awaits Investors - directorstalkinterviews.com
BlackRock (RNA holder) discloses 6.6% Atrium Therapeutics stake in amended ownership filing - Stock Titan
Atrium Therapeutics, Inc. Revenue Breakdown – NASDAQ:RNA - tradingview.com
Atrium Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift StockEarnings Forecast Report - dars.gov.et
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Atrium Therapeutics’ new hire receives options and 3,500 stock units - Stock Titan
Atrium Therapeutics (RNA): Flat Trading as Stock Hovers Near Key Support LevelsMonthly Profile - dars.gov.et
Wells Fargo Remains a Buy on Atrium Therapeutics, Inc. (RNA) - The Globe and Mail
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower-Than-Expected Loss as Pre-Commercial Spend Weighs on ResultsQuarterly Profit Report - dars.gov.et
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower-Than-Expected Loss Provides a Modest SurpriseLow Estimate Range - dars.gov.et
Wells Fargo Maintains Atrium Therapeutics(RNA.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Atrium’s ATR-1072 gains IND clearance for PRKAG2 syndrome - BioWorld News
Atrium Therapeutics Receives FDA Clearance for ATR 1072, Launches First Clinical Trial Targeting PRKAG2 Syndrome - Minichart
FDA Clears Atrium Therapeutics' IND Application for Cardiomyopathy Drug - dicardiology.com
Atrium Therapeutics (Nasdaq: RNA) prepares Corventis PRKAG2 trial launch - Stock Titan
Atrium Therapeutics Secures FDA Clearance for ATR 1072 Trial - grafa.com
Atrium gets FDA clearance for PRKAG2 syndrome trial - Investing.com UK
Atrium gets FDA clearance for PRKAG2 syndrome trial By Investing.com - Investing.com Nigeria
FDA clears Atrium Therapeutics' IND for ATR 107... - Pluang
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome - PR Newswire
FDA clears IND for Atrium Therapeutics' ATR 1072 trial - scanx.trade
Atrium Therapeutics (RNA) Slips 3.5% as Biotech Headwinds IntensifySuperTrend - dars.gov.et
Enterprise value to revenue forward of Atrium Therapeutics, Inc. – NASDAQ:RNA - TradingView
Price to earnings forward of Atrium Therapeutics, Inc. – NASDAQ:RNA - TradingView
Enterprise value to EBIT forward of Atrium Therapeutics, Inc. – NASDAQ:RNA - TradingView
Price to sales forward of Atrium Therapeutics, Inc. – NASDAQ:RNA - TradingView
어비디티 바이오사이언스 (RNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
어비디티 바이오사이언스 주식 (RNA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Boyce Sarah | President and CEO |
Jan 21 '26 |
Sale |
72.45 |
14,387 |
1,042,338 |
269,007 |
| Flanagan W. Michael | Chief Scientific Officer |
Jan 21 '26 |
Sale |
72.45 |
6,534 |
473,388 |
85,093 |
| MacLean Michael F | Chief Financial Officer |
Jan 21 '26 |
Sale |
72.45 |
4,542 |
329,068 |
59,290 |
| LEVIN ARTHUR A | Director |
Jan 21 '26 |
Sale |
72.45 |
1,758 |
127,367 |
16,562 |
| McCarthy Teresa | Chief Human Resources Officer |
Jan 21 '26 |
Sale |
72.45 |
2,929 |
212,206 |
113,938 |
| Boyce Sarah | President and CEO |
Jan 07 '26 |
Sale |
72.23 |
8,576 |
619,444 |
283,394 |
| Calderaro Charles III | Chief Technical Officer |
Jan 07 '26 |
Sale |
72.23 |
3,727 |
269,201 |
49,797 |
| McCarthy Teresa | Chief Human Resources Officer |
Jan 07 '26 |
Sale |
72.23 |
1,965 |
141,932 |
116,867 |
| Moriarty John B | Chief Legal Officer |
Jan 07 '26 |
Sale |
72.23 |
2,374 |
171,474 |
74,557 |
| MacLean Michael F | Chief Financial Officer |
Jan 07 '26 |
Sale |
72.23 |
1,974 |
142,582 |
63,832 |
2.67%
0.04%
자본화:
|
볼륨(24시간):